{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:56:15Z","timestamp":1783734975542,"version":"3.55.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T00:00:00Z","timestamp":1633219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T00:00:00Z","timestamp":1633219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). At present, the COVID-19 has been prevalent worldwide for more than a year and caused more than four million deaths. Liver injury was frequently observed in patients with COVID-19. Recently, a new definition of metabolic dysfunction associated fatty liver disease (MAFLD) was proposed by a panel of international experts, and the relationship between MAFLD and COVID-19 has been actively investigated. Several previous studies indicated that the patients with MAFLD had a higher prevalence of COVID-19 and a tendency to develop severe type of respiratory infection, and others indicated that liver injury would be exacerbated in the patients with MAFLD once infected with COVID-19. The mechanism underlying the relationship between MAFLD and COVID-19 infection has not been thoroughly investigated, and recent studies indicated that multifactorial mechanisms, such as altered host angiotensin converting enzyme 2 (ACE2) receptor expression, direct viral attack, disruption of cholangiocyte function, systemic inflammatory reaction, drug-induced liver injury, hepatic ischemic and hypoxic injury, and MAFLD-related glucose and lipid metabolic disorders, might jointly contribute to both of the adverse hepatic and respiratory outcomes. In this review, we discussed the relationship between MAFLD and COVID-19 based on current available literature, and summarized the recommendations for clinical management of MAFLD patients during the pandemic of COVID-19.<\/jats:p>","DOI":"10.1186\/s12944-021-01564-z","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T16:03:58Z","timestamp":1633363438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management"],"prefix":"10.1186","volume":"20","author":[{"given":"Yanlan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5650-0165","authenticated-orcid":false,"given":"Mingfeng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,3]]},"reference":[{"key":"1564_CR1","unstructured":"World Health Organization. Q&As on COVID-19 and related health topics. World Health Organization; 2020. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/question-and-answers-hub"},{"key":"1564_CR2","unstructured":"World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization; 2020. Available from: https:\/\/covid19.who.int\/"},{"key":"1564_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biochi.2020.09.018","volume":"179","author":"S Muralidar","year":"2020","unstructured":"Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85\u2013100. https:\/\/doi.org\/10.1016\/j.biochi.2020.09.018.","journal-title":"Biochimie"},{"key":"1564_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.14218\/JCTH.2020.00019","volume":"8","author":"J Li","year":"2020","unstructured":"Li J, Fan JG. Characteristics and mechanism of liver injury in 2019 coronavirus disease. J Clin Transl Hepatol. 2020;8:13\u20137. https:\/\/doi.org\/10.14218\/JCTH.2020.00019.","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"1564_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/2050640620924157","volume":"8","author":"SA Alqahtani","year":"2020","unstructured":"Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United European Gastroenterol J. 2020;8(5):509\u201319. https:\/\/doi.org\/10.1177\/2050640620924157.","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"1564_CR6","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jfma.2020.04.020","volume":"119","author":"TH Su","year":"2020","unstructured":"Su TH, Kao JH. The clinical manifestations and management of COVID-19-related liver injury. J Formos Med Assoc. 2020;119(6):1016\u20138. https:\/\/doi.org\/10.1016\/j.jfma.2020.04.020.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"1564_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"issue":"9","key":"1564_CR8","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14548","volume":"40","author":"S Lin","year":"2020","unstructured":"Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082\u20139. https:\/\/doi.org\/10.1111\/liv.14548.","journal-title":"Liver Int"},{"issue":"10","key":"1564_CR9","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.cgh.2020.10.046","volume":"19","author":"V Wai-Sun Wong","year":"2020","unstructured":"Wai-Sun Wong V, Lai-Hung Wong G, Woo J, Abrigo JM, Ka-Man Chan C, She-Ting Shu S, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2020;19(10):2161\u201371.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1564_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/17474124.2021.1860019","volume":"15","author":"Y Yilmaz","year":"2021","unstructured":"Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol. 2021;15(4):345\u201352. https:\/\/doi.org\/10.1080\/17474124.2021.1860019.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"1564_CR11","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672\u201382. https:\/\/doi.org\/10.1002\/hep.30251.","journal-title":"Hepatology"},{"issue":"5","key":"1564_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1631\/jzus.B2000083","volume":"21","author":"Y Shi","year":"2020","unstructured":"Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020;21(5):343\u201360. https:\/\/doi.org\/10.1631\/jzus.B2000083.","journal-title":"J Zhejiang Univ Sci B"},{"key":"1564_CR13","doi-asserted-by":"publisher","unstructured":"Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12(4). https:\/\/doi.org\/10.3390\/v12040372.","DOI":"10.3390\/v12040372"},{"issue":"2","key":"1564_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.dld.2020.09.007","volume":"53","author":"L Pan","year":"2021","unstructured":"Pan L, Huang P, Xie X, Xu J, Guo D, Jiang Y. Metabolic associated fatty liver disease increases the severity of COVID-19: a meta-analysis. Dig Liver Dis. 2021;53(2):153\u20137. https:\/\/doi.org\/10.1016\/j.dld.2020.09.007.","journal-title":"Dig Liver Dis"},{"key":"1564_CR15","first-page":"229","volume":"03","author":"ZP Qian","year":"2020","unstructured":"Qian ZP, Mei X, Zhang YY, Zou Y, Zhang ZG, Zhu H, et al. Analysis of baseline liver biochemistry in 324 patients with COVID-19 in Shanghai area. Chin J Hepatol. 2020;03:229\u201333.","journal-title":"Chin J Hepatol"},{"key":"1564_CR16","doi-asserted-by":"publisher","first-page":"100057","DOI":"10.1016\/j.metop.2020.100057","volume":"8","author":"S Ghoneim","year":"2020","unstructured":"Ghoneim S, Butt MU, Hamid O, Shah A, Asaad I. The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: a population-based study. Metabol Open. 2020;8:100057. https:\/\/doi.org\/10.1016\/j.metop.2020.100057.","journal-title":"Metabol Open"},{"issue":"7807","key":"1564_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215\u201320. https:\/\/doi.org\/10.1038\/s41586-020-2180-5.","journal-title":"Nature"},{"issue":"4","key":"1564_CR18","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(4):894\u2013904e899. https:\/\/doi.org\/10.1016\/j.cell.2020.03.045.","journal-title":"Cell"},{"key":"1564_CR19","doi-asserted-by":"publisher","first-page":"603409","DOI":"10.1155\/2014\/603409","volume":"2014","author":"W Zhang","year":"2014","unstructured":"Zhang W, Xu YZ, Liu B, Wu R, Yang YY, Xiao XQ, et al. Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. ScientificWorldJournal. 2014;2014:603409\u20137. https:\/\/doi.org\/10.1155\/2014\/603409.","journal-title":"ScientificWorldJournal"},{"issue":"3","key":"1564_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jhep.2020.04.035","volume":"73","author":"L Biquard","year":"2020","unstructured":"Biquard L, Valla D, Rautou PE. No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease. J Hepatol. 2020;73(3):717\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.035.","journal-title":"J Hepatol"},{"key":"1564_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jhep.2020.05.015","volume":"73","author":"L Valenti","year":"2020","unstructured":"Valenti L, Jamialahmadi O, Romeo S. Lack of genetic evidence that fatty liver disease predisposes to COVID-19. J Hepatol. 2020;73:709\u201311.","journal-title":"J Hepatol"},{"issue":"10","key":"1564_CR22","doi-asserted-by":"publisher","first-page":"bqaa112","DOI":"10.1210\/endocr\/bqaa112","volume":"161","author":"R Bansal","year":"2020","unstructured":"Bansal R, Gubbi S, Muniyappa R. Metabolic syndrome and COVID 19: endocrine-immune-vascular interactions shapes clinical course. Endocrinology. 2020;161(10):bqaa112. https:\/\/doi.org\/10.1210\/endocr\/bqaa112.","journal-title":"Endocrinology"},{"issue":"5","key":"1564_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00392-020-01626-9","volume":"109","author":"B Li","year":"2020","unstructured":"Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531\u20138. https:\/\/doi.org\/10.1007\/s00392-020-01626-9.","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"1564_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.dsx.2020.06.016","volume":"14","author":"FF Costa","year":"2020","unstructured":"Costa FF, Ros\u00e1rio WR, Ribeiro Farias AC, de Souza RG, Duarte Gondim RS, Barroso WA. Metabolic syndrome and COVID-19: an update on the associated comorbidities and proposed therapies. Diabetes Metab Syndr. 2020;14(5):809\u201314. https:\/\/doi.org\/10.1016\/j.dsx.2020.06.016.","journal-title":"Diabetes Metab Syndr"},{"key":"1564_CR25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fmed.2020.00398","volume":"7","author":"S Rezasoltani","year":"2020","unstructured":"Rezasoltani S, Hatami B, Yadegar A, Asadzadeh Aghdaei H, Zali MR. How patients with chronic liver diseases succeed to Deal with COVID-19? Front Med (Lausanne). 2020;7:398. https:\/\/doi.org\/10.3389\/fmed.2020.00398.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"1564_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.dld.2020.09.010","volume":"53","author":"MI Metawea","year":"2021","unstructured":"Metawea MI, Yousif WI, Moheb I. COVID 19 and liver: an A-Z literature review. Dig Liver Dis. 2021;53(2):146\u201352. https:\/\/doi.org\/10.1016\/j.dld.2020.09.010.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"1564_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jhep.2020.03.044","volume":"73","author":"D Ji","year":"2020","unstructured":"Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;73(2):451\u20133. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.044.","journal-title":"J Hepatol"},{"issue":"9","key":"1564_CR28","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1111\/liv.14575","volume":"40","author":"YJ Zhou","year":"2020","unstructured":"Zhou YJ, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, et al. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020;40(9):2160\u20133. https:\/\/doi.org\/10.1111\/liv.14575.","journal-title":"Liver Int"},{"issue":"3","key":"1564_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2020.04.027","volume":"73","author":"Y-J Zhou","year":"2020","unstructured":"Zhou Y-J, Zheng KI, Wang X-B, Yan H-D, Sun Q-F, Pan K-H, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020;73(3):719\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.027.","journal-title":"J Hepatol"},{"key":"1564_CR30","doi-asserted-by":"publisher","unstructured":"Bramante C, Tignanelli CJ, Dutta N, Jones E, Tamariz L, Clark JM, et al. Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19. medRxiv [Preprint]. Available from: https:\/\/doi.org\/10.1101\/2020.09.01.20185850.\u00a0 Accessed 25 Sept 2021.","DOI":"10.1101\/2020.09.01.20185850"},{"issue":"3","key":"1564_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.dsx.2021.03.019","volume":"15","author":"A Singh","year":"2021","unstructured":"Singh A, Hussain S, Antony B. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis. Diabetes Metab Syndr. 2021;15(3):813\u201322. https:\/\/doi.org\/10.1016\/j.dsx.2021.03.019.","journal-title":"Diabetes Metab Syndr"},{"key":"1564_CR32","doi-asserted-by":"publisher","first-page":"626425","DOI":"10.3389\/fmed.2021.626425","volume":"8","author":"PJ Hegyi","year":"2021","unstructured":"Hegyi PJ, Vancsa S, Ocskay K, Dembrovszky F, Kiss S, Farkas N, et al. Metabolic associated fatty liver disease is associated with an increased risk of severe COVID-19: a systematic review with meta-analysis. Front Med (Lausanne). 2021;8:626425. https:\/\/doi.org\/10.3389\/fmed.2021.626425.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"1564_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov K, Jorgensen SMD, Thomsen KL, Moller HJ, Vilstrup H, George J, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2019;16(3):145\u201359. https:\/\/doi.org\/10.1038\/s41575-018-0082-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1564_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nrd.2015.3","volume":"15","author":"G Musso","year":"2016","unstructured":"Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15(4):249\u201374. https:\/\/doi.org\/10.1038\/nrd.2015.3.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1564_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.14218\/JCTH.2020.00018","volume":"8","author":"G Feng","year":"2020","unstructured":"Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020;8(1):18\u201324. https:\/\/doi.org\/10.14218\/JCTH.2020.00018.","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"1564_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/hep.22350","volume":"48","author":"D van der Poorten","year":"2008","unstructured":"van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48(2):449\u201357. https:\/\/doi.org\/10.1002\/hep.22350.","journal-title":"Hepatology"},{"key":"1564_CR37","doi-asserted-by":"publisher","first-page":"604100","DOI":"10.3389\/fendo.2021.604100","volume":"12","author":"F Gao","year":"2021","unstructured":"Gao F, Zheng KI, Yan HD, Sun QF, Pan KH, Wang TY, et al. Association and interaction between serum Interleukin-6 levels and metabolic dysfunction-associated fatty liver disease in patients with severe coronavirus disease 2019. Front Endocrinol (Lausanne). 2021;12:604100. https:\/\/doi.org\/10.3389\/fendo.2021.604100.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1564_CR38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14218\/JCTH.2019.00051","volume":"8","author":"R Kumar","year":"2020","unstructured":"Kumar R, Priyadarshi RN, Anand U. Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations. J Clin Transl Hepatol. 2020;8(1):76\u201386. https:\/\/doi.org\/10.14218\/JCTH.2019.00051.","journal-title":"J Clin Transl Hepatol"},{"issue":"12","key":"1564_CR39","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/jmcb\/mjaa054","volume":"12","author":"J Wang","year":"2020","unstructured":"Wang J, Meng W. COVID-19 and diabetes: the contributions of hyperglycemia. J Mol Cell Biol. 2020;12(12):958\u201362. https:\/\/doi.org\/10.1093\/jmcb\/mjaa054.","journal-title":"J Mol Cell Biol"},{"issue":"7","key":"1564_CR40","doi-asserted-by":"publisher","first-page":"e3319","DOI":"10.1002\/dmrr.3319","volume":"36","author":"W Guo","year":"2020","unstructured":"Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7):e3319. https:\/\/doi.org\/10.1002\/dmrr.3319.","journal-title":"Diabetes Metab Res Rev"},{"key":"1564_CR41","doi-asserted-by":"publisher","unstructured":"Frasca D, McElhaney J. Influence of obesity on pneumococcus infection risk in the elderly. Front Endocrinol. 2019;10. https:\/\/doi.org\/10.3389\/fendo.2019.00071.","DOI":"10.3389\/fendo.2019.00071"},{"issue":"12","key":"1564_CR42","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/obr.12320","volume":"16","author":"NV Dhurandhar","year":"2015","unstructured":"Dhurandhar NV, Bailey D, Thomas D. Interaction of obesity and infections. Obes Rev. 2015;16(12):1017\u201329. https:\/\/doi.org\/10.1111\/obr.12320.","journal-title":"Obes Rev"},{"issue":"6","key":"1564_CR43","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.chest.2015.12.034","volume":"149","author":"CW Baffi","year":"2016","unstructured":"Baffi CW, Wood L, Winnica D, Strollo PJ Jr, Gladwin MT, Que LG, et al. Metabolic syndrome and the lung. Chest. 2016;149(6):1525\u201334. https:\/\/doi.org\/10.1016\/j.chest.2015.12.034.","journal-title":"Chest"},{"issue":"10","key":"1564_CR44","doi-asserted-by":"publisher","first-page":"e0240400","DOI":"10.1371\/journal.pone.0240400","volume":"15","author":"R Forlano","year":"2020","unstructured":"Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, et al. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 2020;15(10):e0240400. https:\/\/doi.org\/10.1371\/journal.pone.0240400.","journal-title":"PLoS One"},{"issue":"2","key":"1564_CR45","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jhep.2020.09.006","volume":"74","author":"K Mushtaq","year":"2021","unstructured":"Mushtaq K, Khan MU, Iqbal F, Alsoub DH, Chaudhry HS, Ata F, et al. NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - the debate continues. J Hepatol. 2021;74(2):482\u20134. https:\/\/doi.org\/10.1016\/j.jhep.2020.09.006.","journal-title":"J Hepatol"},{"key":"1564_CR46","doi-asserted-by":"publisher","first-page":"100271","DOI":"10.1016\/j.aohep.2020.09.015","volume":"20","author":"I Lopez-Mendez","year":"2021","unstructured":"Lopez-Mendez I, Aquino-Matus J, Gall SM, Prieto-Nava JD, Juarez-Hernandez E, Uribe M, et al. Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19). Ann Hepatol. 2021;20:100271. https:\/\/doi.org\/10.1016\/j.aohep.2020.09.015.","journal-title":"Ann Hepatol"},{"key":"1564_CR47","doi-asserted-by":"publisher","first-page":"m1501","DOI":"10.1136\/bmj.m1501","volume":"369","author":"S Gerry","year":"2020","unstructured":"Gerry S, Bonnici T, Birks J, Kirtley S, Virdee PS, Watkinson PJ, et al. Early warning scores for detecting deterioration in adult hospital patients: systematic review and critical appraisal of methodology. BMJ. 2020;369:m1501. https:\/\/doi.org\/10.1136\/bmj.m1501.","journal-title":"BMJ"},{"issue":"1","key":"1564_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/gutjnl-2020-320995","volume":"70","author":"D Petroff","year":"2021","unstructured":"Petroff D, Batz O, Jedrysiak K, Kramer J, Berg T, Wiegand J. Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples. Gut. 2021;70(1):219\u201321. https:\/\/doi.org\/10.1136\/gutjnl-2020-320995.","journal-title":"Gut"},{"issue":"12","key":"1564_CR49","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/hep4.1592","volume":"4","author":"R Huang","year":"2020","unstructured":"Huang R, Zhu L, Wang J, Xue L, Liu L, Yan X, et al. Clinical features of COVID-19 patients with non-alcoholic fatty liver disease. Hepatol Commun. 2020;4(12):1758\u201368. https:\/\/doi.org\/10.1002\/hep4.1592.","journal-title":"Hepatol Commun"},{"issue":"5","key":"1564_CR50","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.dld.2021.01.019","volume":"53","author":"A Campos-Murguia","year":"2021","unstructured":"Campos-Murguia A, Roman-Calleja BM, Toledo-Coronado IV, Gonzalez-Regueiro JA, Solis-Ortega AA, Kusulas-Delint D, et al. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19. Dig Liver Dis. 2021;53(5):525\u201333. https:\/\/doi.org\/10.1016\/j.dld.2021.01.019.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"1564_CR51","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.2337\/dc10-2229","volume":"34","author":"RM Williamson","year":"2011","unstructured":"Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2011;34(5):1139\u201344. https:\/\/doi.org\/10.2337\/dc10-2229.","journal-title":"Diabetes Care"},{"issue":"5","key":"1564_CR52","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2337\/dc06-2247","volume":"30","author":"G Targher","year":"2007","unstructured":"Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212\u20138. https:\/\/doi.org\/10.2337\/dc06-2247.","journal-title":"Diabetes Care"},{"issue":"8","key":"1564_CR53","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.metabol.2016.01.001","volume":"65","author":"JM Hazlehurst","year":"2016","unstructured":"Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65(8):1096\u2013108. https:\/\/doi.org\/10.1016\/j.metabol.2016.01.001.","journal-title":"Metabolism"},{"issue":"2","key":"1564_CR54","doi-asserted-by":"publisher","first-page":"e3377","DOI":"10.1002\/dmrr.3377","volume":"37","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2021;37(2):e3377. https:\/\/doi.org\/10.1002\/dmrr.3377.","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"1564_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","volume":"17","author":"S Lim","year":"2021","unstructured":"Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11\u201330. https:\/\/doi.org\/10.1038\/s41574-020-00435-4.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1564_CR56","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/jmv.26227","volume":"93","author":"SM Smith","year":"2021","unstructured":"Smith SM, Boppana A, Traupman JA, Unson E, Maddock DA, Chao K, et al. Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. J Med Virol. 2021;93(1):409\u201315. https:\/\/doi.org\/10.1002\/jmv.26227.","journal-title":"J Med Virol"},{"issue":"1","key":"1564_CR57","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/0194599820929640","volume":"163","author":"K Hur","year":"2020","unstructured":"Hur K, Price CPE, Gray EL, Gulati RK, Maksimoski M, Racette SD, et al. Factors associated with intubation and prolonged intubation in hospitalized patients with COVID-19. Otolaryngol Head Neck Surg. 2020;163(1):170\u20138. https:\/\/doi.org\/10.1177\/0194599820929640.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"1564_CR58","doi-asserted-by":"publisher","first-page":"154262","DOI":"10.1016\/j.metabol.2020.154262","volume":"108","author":"L Palaiodimos","year":"2020","unstructured":"Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262.","journal-title":"Metabolism"},{"issue":"4","key":"1564_CR59","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1177\/1932296820924469","volume":"14","author":"B Bode","year":"2020","unstructured":"Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813\u201321. https:\/\/doi.org\/10.1177\/1932296820924469.","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"1564_CR60","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.cmet.2020.04.021","volume":"31","author":"L Zhu","year":"2020","unstructured":"Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068\u201377e1063. https:\/\/doi.org\/10.1016\/j.cmet.2020.04.021.","journal-title":"Cell Metab"},{"key":"1564_CR61","doi-asserted-by":"publisher","unstructured":"Patel SY, McCoy RG, Barnett ML, Shah ND, Mehrotra A. Diabetes care and glycemic control during the COVID-19 pandemic in the United States. JAMA Intern Med. 2021. https:\/\/doi.org\/10.1001\/jamainternmed.2021.3047.","DOI":"10.1001\/jamainternmed.2021.3047"},{"issue":"7","key":"1564_CR62","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/jmv.25887","volume":"92","author":"A Brufsky","year":"2020","unstructured":"Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J Med Virol. 2020;92(7):770\u20135. https:\/\/doi.org\/10.1002\/jmv.25887.","journal-title":"J Med Virol"},{"key":"1564_CR63","doi-asserted-by":"publisher","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020(382):1708\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2002032.","DOI":"10.1056\/NEJMoa2002032"},{"issue":"9","key":"1564_CR64","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1007\/s00261-020-02648-7","volume":"45","author":"AK Medeiros","year":"2020","unstructured":"Medeiros AK, Barbisan CC, Cruz IR, de Ara\u00fajo EM, Lib\u00e2nio BB, Albuquerque KS, et al. Higher frequency of hepatic steatosis at CT among COVID-19-positive patients. Abdom Radiol. 2020;45(9):2748\u201354. https:\/\/doi.org\/10.1007\/s00261-020-02648-7.","journal-title":"Abdom Radiol"},{"key":"1564_CR65","doi-asserted-by":"publisher","unstructured":"Chai XQ, Hu LF, Zhang Y, Han WY, Lu Z, Ke AW, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. BioRxiv preprint. 2020. https:\/\/doi.org\/10.1101\/2020.02.03.931766.","DOI":"10.1101\/2020.02.03.931766"},{"issue":"4","key":"1564_CR66","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jhep.2020.05.002","volume":"73","author":"Y Wang","year":"2020","unstructured":"Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;73(4):807\u201316. https:\/\/doi.org\/10.1016\/j.jhep.2020.05.002.","journal-title":"J Hepatol"},{"issue":"3","key":"1564_CR67","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00535-021-01760-9","volume":"56","author":"D Li","year":"2021","unstructured":"Li D, Ding X, Xie M, Tian D, Xia L. COVID-19-associated liver injury: from bedside to bench. J Gastroenterol. 2021;56(3):218\u201330. https:\/\/doi.org\/10.1007\/s00535-021-01760-9.","journal-title":"J Gastroenterol"},{"issue":"6","key":"1564_CR68","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355\u201362. https:\/\/doi.org\/10.1038\/s41577-020-0331-4.","journal-title":"Nat Rev Immunol"},{"issue":"21","key":"1564_CR69","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1007\/s00018-004-4242-5","volume":"61","author":"JH Kuhn","year":"2004","unstructured":"Kuhn JH, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cell Mol Life Sci. 2004;61(21):2738\u201343. https:\/\/doi.org\/10.1007\/s00018-004-4242-5.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"1564_CR70","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631\u20137. https:\/\/doi.org\/10.1002\/path.1570.","journal-title":"J Pathol"},{"issue":"32","key":"1564_CR71","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.3748\/wjg.v26.i32.4753","volume":"26","author":"RX Yang","year":"2020","unstructured":"Yang RX, Zheng RD, Fan JG. Etiology and management of liver injury in patients with COVID-19. World J Gastroenterol. 2020;26(32):4753\u201362. https:\/\/doi.org\/10.3748\/wjg.v26.i32.4753.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"1564_CR72","doi-asserted-by":"publisher","first-page":"e13338","DOI":"10.1111\/eci.13338","volume":"50","author":"P Portincasa","year":"2020","unstructured":"Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: two intersecting pandemics. Eur J Clin Investig. 2020;50(10):e13338. https:\/\/doi.org\/10.1111\/eci.13338.","journal-title":"Eur J Clin Investig"},{"issue":"3","key":"1564_CR73","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1136\/gutjnl-2020-321913","volume":"70","author":"K Zhan","year":"2021","unstructured":"Zhan K, Liao S, Li J, Bai Y, Lv L, Yu K, et al. Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation. Gut. 2021;70(3):628\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2020-321913.","journal-title":"Gut"},{"issue":"6490","key":"1564_CR74","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473\u20134. https:\/\/doi.org\/10.1126\/science.abb8925.","journal-title":"Science"},{"key":"1564_CR75","doi-asserted-by":"publisher","first-page":"102763","DOI":"10.1016\/j.ebiom.2020.102763","volume":"55","author":"J Liu","year":"2020","unstructured":"Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102763.","journal-title":"EBioMedicine"},{"issue":"1","key":"1564_CR76","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","volume":"108","author":"J Wang","year":"2020","unstructured":"Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17\u201341. https:\/\/doi.org\/10.1002\/JLB.3COVR0520-272R.","journal-title":"J Leukoc Biol"},{"issue":"6","key":"1564_CR77","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.cgh.2018.11.037","volume":"17","author":"ZP Fricker","year":"2019","unstructured":"Fricker ZP, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Benjamin EJ, et al. Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the Framingham heart study. Clin Gastroenterol Hepatol. 2019;17(6):1157\u201364e1154. https:\/\/doi.org\/10.1016\/j.cgh.2018.11.037.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1564_CR78","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ijcard.2018.01.046","volume":"259","author":"TG Simon","year":"2018","unstructured":"Simon TG, Trejo MEP, McClelland R, Bradley R, Blaha MJ, Zeb I, et al. Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis. Int J Cardiol. 2018;259:198\u2013204. https:\/\/doi.org\/10.1016\/j.ijcard.2018.01.046.","journal-title":"Int J Cardiol"},{"issue":"6","key":"1564_CR79","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1053\/j.gastro.2016.09.048","volume":"151","author":"B McDonald","year":"2016","unstructured":"McDonald B, Kubes P. Innate immune cell trafficking and function during sterile inflammation of the liver. Gastroenterology. 2016;151(6):1087\u201395. https:\/\/doi.org\/10.1053\/j.gastro.2016.09.048.","journal-title":"Gastroenterology"},{"issue":"10223","key":"1564_CR80","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5.","journal-title":"Lancet"},{"issue":"21","key":"1564_CR81","first-page":"125","volume":"2020","author":"QY Gao","year":"2019","unstructured":"Gao QY, Chen YX, Fang JY. Novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2019;2020(21):125\u20136.","journal-title":"J Dig Dis"},{"issue":"1","key":"1564_CR82","doi-asserted-by":"publisher","first-page":"27665","DOI":"10.1038\/srep27665","volume":"6","author":"J Xie","year":"2016","unstructured":"Xie J, Yang L, Tian L, Li W, Yang L, Li L. Macrophage migration inhibitor factor upregulates MCP-1 expression in an autocrine manner in hepatocytes during acute mouse liver injury. Sci Rep. 2016;6(1):27665. https:\/\/doi.org\/10.1038\/srep27665.","journal-title":"Sci Rep"},{"issue":"4","key":"1564_CR83","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420\u20132. https:\/\/doi.org\/10.1016\/S2213-2600(20)30076-X.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1564_CR84","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41392-020-00373-7","volume":"5","author":"P Zhong","year":"2020","unstructured":"Zhong P, Xu J, Yang D, Shen Y, Wang L, Feng Y, et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. Signal Transduct Target Ther. 2020;5(1):256. https:\/\/doi.org\/10.1038\/s41392-020-00373-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"10234","key":"1564_CR85","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(20)30937-5.","journal-title":"Lancet"},{"issue":"2","key":"1564_CR86","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular Endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120\u20138. https:\/\/doi.org\/10.1056\/NEJMoa2015432.","journal-title":"N Engl J Med"},{"issue":"2","key":"1564_CR87","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/his.14160","volume":"77","author":"AN Duarte-Neto","year":"2020","unstructured":"Duarte-Neto AN, Monteiro RAA, da Silva LFF, Malheiros D, de Oliveira EP, Theodoro-Filho J, et al. Pulmonary and systemic involvement in COVID-19 patients assessed with ultrasound-guided minimally invasive autopsy. Histopathology. 2020;77(2):186\u201397. https:\/\/doi.org\/10.1111\/his.14160.","journal-title":"Histopathology"},{"issue":"6","key":"1564_CR88","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.diabet.2020.06.001","volume":"46","author":"G Targher","year":"2020","unstructured":"Targher G, Mantovani A, Byrne CD, Wang XB, Yan HD, Sun QF, et al. Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. Diabetes Metab. 2020;46(6):505\u20137. https:\/\/doi.org\/10.1016\/j.diabet.2020.06.001.","journal-title":"Diabetes Metab"},{"issue":"5","key":"1564_CR89","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jth.14817","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094\u20139. https:\/\/doi.org\/10.1111\/jth.14817.","journal-title":"J Thromb Haemost"},{"key":"1564_CR90","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.biochi.2020.08.018","volume":"179","author":"PJ Ferron","year":"2020","unstructured":"Ferron PJ, Gicquel T, Megarbane B, Clement B, Fromenty B. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: a potential threat for drug-induced liver injury? Biochimie. 2020;179:266\u201374. https:\/\/doi.org\/10.1016\/j.biochi.2020.08.018.","journal-title":"Biochimie"},{"issue":"4","key":"1564_CR91","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/apt.15916","volume":"52","author":"AV Kulkarni","year":"2020","unstructured":"Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020;52(4):584\u201399. https:\/\/doi.org\/10.1111\/apt.15916.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1564_CR92","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40264-020-00954-z","volume":"43","author":"A Olry","year":"2020","unstructured":"Olry A, Meunier L, Delire B, Larrey D, Horsmans Y, Le Louet H. Drug-induced liver injury and COVID-19 infection: the rules remain the same. Drug Saf. 2020;43(7):615\u20137. https:\/\/doi.org\/10.1007\/s40264-020-00954-z.","journal-title":"Drug Saf"},{"issue":"1","key":"1564_CR93","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-020-00363-9","volume":"5","author":"S Liao","year":"2020","unstructured":"Liao S, Zhan K, Gan L, Bai Y, Li J, Yuan G, et al. Inflammatory cytokines, T lymphocyte subsets, and ritonavir involved in liver injury of COVID-19 patients. Signal Transduct Target Ther. 2020;5(1):255. https:\/\/doi.org\/10.1038\/s41392-020-00363-9.","journal-title":"Signal Transduct Target Ther"},{"key":"1564_CR94","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061\u20139. https:\/\/doi.org\/10.1001\/jama.2020.1585.","journal-title":"JAMA"},{"key":"1564_CR95","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/hep.31684","volume":"74","author":"A Saviano","year":"2021","unstructured":"Saviano A, Wrensch F, Ghany MG, Baumert TF. Liver disease and coronavirus disease 2019: from pathogenesis to clinical care. Hepatology. 2021;74:1088\u2013100. https:\/\/doi.org\/10.1002\/hep.31684.","journal-title":"Hepatology"},{"issue":"7","key":"1564_CR96","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/liv.12514","volume":"34","author":"A Michaut","year":"2014","unstructured":"Michaut A, Moreau C, Robin M-A, Fromenty B. Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int. 2014;34(7):e171\u20139. https:\/\/doi.org\/10.1111\/liv.12514.","journal-title":"Liver Int"},{"issue":"3","key":"1564_CR97","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/00000441-197303000-00001","volume":"265","author":"GD Dunn","year":"1973","unstructured":"Dunn GD, Hayes P, Breen KJ, Schenker S. The liver in congestive heart failure: a review. Am J Med Sci. 1973;265(3):174\u201389. https:\/\/doi.org\/10.1097\/00000441-197303000-00001.","journal-title":"Am J Med Sci"},{"issue":"1","key":"1564_CR98","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41574-018-0096-z","volume":"15","author":"FJ Gonzalez","year":"2018","unstructured":"Gonzalez FJ, Xie C, Jiang C. The role of hypoxia-inducible factors in metabolic diseases. Nat Rev Endocrinol. 2018;15(1):21\u201332. https:\/\/doi.org\/10.1038\/s41574-018-0096-z.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1564_CR99","doi-asserted-by":"publisher","first-page":"E710","DOI":"10.1152\/ajpendo.00052.2019","volume":"317","author":"J Chen","year":"2019","unstructured":"Chen J, Chen J, Fu H, Li Y, Wang L, Luo S, et al. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2alpha\/PPARalpha pathway. Am J Physiol Endocrinol Metab. 2019;317(4):E710\u201322. https:\/\/doi.org\/10.1152\/ajpendo.00052.2019.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"1564_CR100","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.jhep.2020.06.006","volume":"73","author":"D Jothimani","year":"2020","unstructured":"Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. 2020;73(5):1231\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2020.06.006.","journal-title":"J Hepatol"},{"issue":"8","key":"1564_CR101","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1053\/j.gastro.2016.01.025","volume":"150","author":"B Gao","year":"2016","unstructured":"Gao B, Tsukamoto H. Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe? Gastroenterology. 2016;150(8):1704\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.025.","journal-title":"Gastroenterology"},{"key":"1564_CR102","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2020.05.035","volume":"77","author":"P Portincasa","year":"2020","unstructured":"Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med. 2020;77:18\u201324. https:\/\/doi.org\/10.1016\/j.ejim.2020.05.035.","journal-title":"Eur J Intern Med"},{"issue":"10","key":"1564_CR103","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1111\/liv.14484","volume":"40","author":"GH Prins","year":"2020","unstructured":"Prins GH, Olinga P. Potential implications of COVID-19 in non-alcoholic fatty liver disease. Liver Int. 2020;40(10):2568. https:\/\/doi.org\/10.1111\/liv.14484.","journal-title":"Liver Int"},{"issue":"5","key":"1564_CR104","doi-asserted-by":"publisher","first-page":"100169","DOI":"10.1016\/j.jhepr.2020.100169","volume":"2","author":"T Boettler","year":"2020","unstructured":"Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, et al. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Reports. 2020;2(5):100169. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100169.","journal-title":"JHEP Reports"},{"key":"1564_CR105","doi-asserted-by":"publisher","first-page":"273","DOI":"10.5144\/0256-4947.2020.273","volume":"40","author":"SA Alqahtani","year":"2020","unstructured":"Alqahtani SA, Aljumah AA, Hashim A, Alenazi TH, AlJawad M, Al Hamoudi WK, et al. Principles of Care for Patients with liver disease during the coronavirus disease 2019 (COVID-19) pandemic: position statement of the Saudi Association for the Study of liver disease and transplantation. Ann Saudi Med. 2020;40:273\u201380. https:\/\/doi.org\/10.5144\/0256-4947.2020.273.","journal-title":"Ann Saudi Med"},{"issue":"8","key":"1564_CR106","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2468-1253(20)30190-4","volume":"5","author":"GL-H Wong","year":"2020","unstructured":"Wong GL-H, Wong VW-S, Thompson A, Jia J, Hou J, Lesmana CRA, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020;5(8):776\u201387. https:\/\/doi.org\/10.1016\/S2468-1253(20)30190-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1564_CR107","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202001.0358.v3","volume-title":"Potential natural compounds for preventing SARS-CoV-2 (2019-nCoV) infection","author":"H Chen","year":"2020","unstructured":"Chen H, Du Q. Potential natural compounds for preventing SARS-CoV-2 (2019-nCoV) infection; 2020."},{"issue":"8","key":"1564_CR108","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782\u201393. https:\/\/doi.org\/10.1001\/jama.2020.12839.","journal-title":"JAMA"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01564-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01564-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01564-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T16:45:02Z","timestamp":1633365902000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01564-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,3]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01564-z","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,3]]},"assertion":[{"value":"1 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}